Pujiang Prostate Cancer Summit | Professor Jianming Guo: Breaking Through CRPC Resistance and Why Cytoreductive Surgery for Oligometastatic Disease Is Emerging as the Next Frontier

Pujiang Prostate Cancer Summit | Professor Jianming Guo: Breaking Through CRPC Resistance and Why Cytoreductive Surgery for Oligometastatic Disease Is Emerging as the Next Frontier

The 2026 Pujiang Prostate Cancer Summit was successfully held in Shanghai on June 26–27. Hosted by the Shanghai Anti-Cancer Association and organized by Fudan University Shanghai Cancer Center, the meeting brought together leading experts through keynote lectures, multidisciplinary (MDT) discussions, and live surgical demonstrations to highlight the latest advances in prostate cancer management. Among the meeting's major themes, personalized and precision treatment strategies attracted particular attention.
Pujiang Prostate Cancer Summit | Professor Dingwei Ye: Expanding Early Screening, Standardizing Care, and Advancing Clinical Research—Three Pillars to Narrow China’s Prostate Cancer Survival Gap

Pujiang Prostate Cancer Summit | Professor Dingwei Ye: Expanding Early Screening, Standardizing Care, and Advancing Clinical Research—Three Pillars to Narrow China’s Prostate Cancer Survival Gap

The 2026 Pujiang Prostate Cancer Summit was held in Shanghai on June 26–27 under the theme "Standardization, Precision, Chinese Innovation, and Global Collaboration." The meeting brought together leading experts in genitourinary oncology to showcase the latest advances in standardized prostate cancer management and innovative treatment strategies.
Clear Horizons, Comprehensive Urologic Care | Professor Xin Yao: ADT Remains the Cornerstone of Prostate Cancer Management, While LHRH Antagonists Deliver Both Clinical Efficacy and Quality of Life

Clear Horizons, Comprehensive Urologic Care | Professor Xin Yao: ADT Remains the Cornerstone of Prostate Cancer Management, While LHRH Antagonists Deliver Both Clinical Efficacy and Quality of Life

In this edition of Clear Horizons, Comprehensive Urologic Care, Professor Xin Yao from Tianjin Medical University Cancer Institute and Hospital discusses the mechanistic and clinical differences between LHRH agonists and antagonists, as well as practical strategies for managing ADT-related adverse events to maximize both treatment efficacy and patient quality of life.
APPLE 2026 | Prof. Stephen L. Chan: The Art and Science of Conversion Therapy in Cholangiocarcinoma 

APPLE 2026 | Prof. Stephen L. Chan: The Art and Science of Conversion Therapy in Cholangiocarcinoma 

Cholangiocarcinoma is characterized by its high malignancy, with the majority of patients presenting with unresectable disease at initial diagnosis. In recent years, conversion therapy—which utilizes systemic treatment to downsize tumors—has emerged as a pivotal, offering select patients a pathway to curative-intent resection. However, striking the right balance between therapeutic efficacy and overtreatment remains a significant clinical challenge. At APPLE 2026, Prof. Stephen L. Chan, from the Chinese University of Hong Kong (CUHK) Faculty of Medicine, offered an in-depth analysis of these issues during an exclusive interview with our journal. Prof. Chen advocates for earlier genomic testing for alterations such as FGFR2 and IDH1, and proposes a multidimensional assessment framework combining radiology with circulating biomarkers like ctDNA and MRD to precisely identify the optimal surgical window. Furthermore, he recommends a stratified postoperative strategy guided by pathological response (MPR/pCR) to maximize recurrence-free survival.
APACC 2026 | Prof. Jason Ong: Tackling PrEP Accessibility Challenges and Exploring AI-Driven New Pathways for STI Prevention and Control 

APACC 2026 | Prof. Jason Ong: Tackling PrEP Accessibility Challenges and Exploring AI-Driven New Pathways for STI Prevention and Control 

The 2026 Asia-Pacific AIDS and Co-infections Conference (APACC 2026) was successfully held in Tokyo, Japan. Focusing on cutting-edge practices and technological innovations in the prevention and control of HIV and sexually transmitted infections, the conference gathered global experts in the field to explore pathways for optimizing public health services. Our journal specially invited Professor Jason Ong from the Melbourne Sexual Health Centre in Australia for an in-depth interview.
APACC 2026| Researcher Johanna Beulah Sornillo: Rapid ART Initiation to Fortify HIV Prevention and Control in the Asia-Pacific 

APACC 2026| Researcher Johanna Beulah Sornillo: Rapid ART Initiation to Fortify HIV Prevention and Control in the Asia-Pacific 

The 11th Asia-Pacific AIDS & Co-Infections Conference (APACC 2026) was successfully convened in Tokyo, Japan. Bringing together HIV prevention and control experts from across the region, the conference focused on core regional challenges including standardized antiretroviral therapy (ART) and whole-course management for people living with HIV, serving as an exchange platform to advance the optimization of HIV diagnosis and treatment in the Asia-Pacific.
APPLE 2026 | Prof. Masatoshi Kudo: Reconstructing Systemic-Locoregional Therapeutic Strategies for Hepatocellular Carcinoma in the Immuno-Oncology Era 

APPLE 2026 | Prof. Masatoshi Kudo: Reconstructing Systemic-Locoregional Therapeutic Strategies for Hepatocellular Carcinoma in the Immuno-Oncology Era 

As hepatocellular carcinoma (HCC) treatment enters the wave of immuno-oncology (IO) combinations, the paradigm of combining systemic therapy with locoregional treatments (LRT) is undergoing a qualitative leap—evolving from incremental gains to a fundamental reconstruction. Held from July 3–5, 2026, the 16th Asia-Pacific Primary Liver Cancer Expert (APPLE) Meeting convened in Shanghai, bringing together leading experts from across the Asia-Pacific, Europe, and North America to discuss novel strategies for liver cancer prevention and management.
APACC 2026 | Rodenie & Patrick: Exploring the Causes of HIV Loss to Follow-Up and Building Comprehensive Care for People Living with HIV Through Innovative Community Services 

APACC 2026 | Rodenie & Patrick: Exploring the Causes of HIV Loss to Follow-Up and Building Comprehensive Care for People Living with HIV Through Innovative Community Services 

The 2026 Asia-Pacific AIDS and Co-infections Conference (APACC 2026) was successfully held in Tokyo, Japan. Focusing on core public health issues such as continuous care for people living with HIV (PLHIV) and co-infection management, the conference gathered frontline clinical researchers from multiple countries to share local prevention and control practices and research findings. Infectious Disease Frontier specially invited Dr. Rodenie Arnaiz Olete, MEARL Lead of Sustained Health Initiatives of the Philippines, and his colleague, Dr. Patrick Eustaquio, Director for Clinical Programs of SAIL Clinics in the Philippines, for an in-depth interview. Combining real-world clinical data from the Philippines, the two discussed practical challenges including factors associated with HIV care disengagements, innovative intervention models in community clinics, and integrated diagnosis and treatment of hepatitis B and HIV co-infection. Integrating research conclusions with frontline clinical practical experience, they provide localized reference ideas for low- and middle-income countries to optimize the continuum of care for PLHIV.
APACC 2026 | Dr. Hay Mar Su Lwin: Focus on Glycemic Abnormalities Among People Living with HIV, Analyze Risk Factors for Diabetes Progression and Asia-Specific Clinical Management Strategies 

APACC 2026 | Dr. Hay Mar Su Lwin: Focus on Glycemic Abnormalities Among People Living with HIV, Analyze Risk Factors for Diabetes Progression and Asia-Specific Clinical Management Strategies 

Editorial Note: The 2026 Asia-Pacific AIDS & Co-infections Conference (APACC 2026) was successfully held in Tokyo, Japan. Centered on the clinical hot topics of metabolic complications in people living with HIV (PLWH), the conference delivered cutting-edge insights for clinical practice across the Asia-Pacific region. During the conference, Infectious Disease Frontier conducted an exclusive interview with Dr. Hay Mar Su Lwin, Research Physician (MBBS MCTM) at the HIV Netherlands Australia Thailand Research Collaboration. Glycemic abnormality is a prevalent metabolic complication among PLWH receiving long-term antiretroviral therapy (ART), and intervention during prediabetes is a critical link in disease prevention and control. Drawing on long-term cohort studies, Dr. Lwin shared in-depth perspectives on risk factors linked to glycemic deterioration in PLWH, metabolic impacts of distinct antiretroviral regimens, and tailored clinical strategies for Asian populations. This interview integrates evidence-based data and practical clinical guidance, offering vital references for clinicians in domestic infectious disease departments to optimize glycemic screening, lifestyle intervention, and individualized selection of ART regimens.
APACC 2026 | Professor Eric Chow: Addressing Antimicrobial Resistance and Adherence Challenges — Analysis of Evidence Base and Implementation Barriers of DoxyPEP for STI Prevention 

APACC 2026 | Professor Eric Chow: Addressing Antimicrobial Resistance and Adherence Challenges — Analysis of Evidence Base and Implementation Barriers of DoxyPEP for STI Prevention 

The 11th Asia-Pacific AIDS & Co-infections Conference (APACC 2026) was successfully held in Tokyo, Japan. The prevention and control of sexually transmitted infections (STIs) has emerged as one of the most heated topics at the conference. To sort out current cutting-edge prevention and control strategies, Infectious Disease Frontier invited Professor Eric Chow from the Melbourne Sexual Health Centre, Monash University, for an exclusive in-depth interview.